CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
2021-01-20
No Comments
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021.
滬公網安備31010402000451號